TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03052907

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BSPAN
Description: 1. Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~2. Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach \& Health Promotion and Delivery \& Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach \& Health Promotion component (Medium Capacity).~3. Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up.
Study: NCT00735696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
Study: NCT01520454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV saline at 0.83 mL/kg/hr for six hours
Study: NCT02678988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
Study: NCT00735696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
Study: NCT02678988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
Study: NCT02511860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Burdock
Description: Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methylcellulose (inert) tablet taken as placebo
Study: NCT01684280

Intervention type: GENETIC
Intervention: gender
Description: Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
Study: NCT01552330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine and Pyronaridine-artesunate
Description: Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine and Pyronaridine-Artesunate
Description: Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets
Study: NCT03023189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
Study: NCT00324896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: eszopiclone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo administered at night
Study: NCT01003951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol.
Study: NCT04192032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred Juul pod flavor (5% nicotine)
Description: Preferred Juul pod flavor (5% nicotine)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic Tobacco Juul pod flavor (5% nicotine)
Description: Classic Tobacco Juul pod flavor (5% nicotine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor with HWL
Description: Preferred flavor (5% nicotine) with HWL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor, 3% nicotine
Description: Preferred flavor, 3% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preferred flavor, 0% nicotine
Description: Preferred flavor, 0% nicotine
Study: NCT01970592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POWER training
Description: Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
Study: NCT03762525

Intervention type: RADIATION
Group type: OTHER
Intervention: ECG gated CTA
Description: Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings.
Study: NCT01520454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV saline at 0.83 mL/kg/hr for six hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Study: NCT02913287

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aquamin/Aquamin MG
Description: Marine-based nutraceutical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Placebo
Description: Maltodextrin Placebo
Study: NCT01520454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Water by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral fat
Description: Soybean oil by mouth at 1.25 g/kg x 2 doses
Study: NCT01978015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost and timolol maleate fixed combination
Description: bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextran and hypromellose
Description: Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
Study: NCT01520454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Study: NCT01267136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine with acetaminophen
Description: Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol suspension
Description: Liquid tramadol 1.05 mg/kg \[=0.3 mL/kg\] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
Study: NCT01520454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Study: NCT04919473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy product:vMCO-I
Description: The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy product:vMCO-I
Description: The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
Study: NCT00534586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TCI 0.5 mcg/ml 1.0 mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-Ketamine
Description: continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: via face mask 0.40 Vol% 0.80 Vol%
Study: NCT03027050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-PRF
Description: Applied for treatment of periodontal bone loss.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-PRF
Description: Applied for treatment of periodontal bone loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement alone
Study: NCT02674828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement for meeting targeted physical activity goals
Description: Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
Study: NCT04638673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix taVNS model 0125-LTE Stimulator - Active-Active Group
Description: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.
Study: NCT04488887

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: patients in all groups will be examined with optical coherence tomography angiography, for every eye 3 macular and 3 papillary scans will be performed by two different OCTA machines, analysis will be carried out to evaluate the repeatability and reproducibility of the test
Study: NCT01045239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse 577 nm yellow diode laser
Description: Laser administered at beginning of study and may be repeated at 16 weeks if needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532 nm green diode laser
Description: Laser administered at beginning of study and may be repeated at 16 weeks if needed
Study: NCT02853214

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis of peripheral blood samples
Description: M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
Study: NCT00903344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4000IU vitamin D3 tablet taken daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin containing 400IU vitamin D in tablet taken daily
Study: NCT03919019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macuprev Group
Description: oral supplementation (Macuprev) 2 capsules per day for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: oral placebo 2 capsules per day for 6 months
Study: NCT02667561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 2.2 mg
Description: Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT04638673

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group
Description: Participants will receive sham taVNS stimulation for weeks 1\&2 and active stimulation for weeks 3\&4 of the stimulation portion of this study.
Study: NCT03306862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole yellow pea soup
Description: Soup containing whole yellow peas

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split yellow pea soup
Description: Soup containing split yellow peas

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potato soup
Description: Soup containing potatoes
Study: NCT01554397

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks with PET-guided Bone Marrow-Sparing
Study: NCT02667561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 4.4 mg
Description: Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1% 8.8 mg
Description: Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Testosterone Gel 1%
Description: Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Study: NCT04787016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate training
Description: Pilates is an exercise training program used to build core strength and flexibility.
Study: NCT03167658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace wellness program
Description: Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
Study: NCT01283945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)
Study: NCT00974532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High calcium diet 2000 mg/day
Description: High calcium (2000 mg elemental calcium) diet x 9 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High calcium diet 2000 mg/day
Description: High calcium (2000 mg elemental calcium) diet x 9 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calcium diet, 800 mg/day
Description: Low calcium (800 mg elemental calcium) diet x 9 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calcium diet, 800 mg/day
Description: Low calcium (800 mg elemental calcium) diet x 9 days
Study: NCT01946269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed Resuscitation Therapy (GDT)
Description: * A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~* The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~* When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~* The final step will be red blood transfusion to reach a hematocrit higher than 28%.~* If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
Study: NCT03362632

Intervention type: DRUG
Intervention: Antibiotics
Description: This is an observation study, no specific antibiotics will be indicated during treatment.
Study: NCT01554397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
Study: NCT02532907

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.